Monday, 20 Nov 2017

You are here

FDA Approves Renflexis as Second Infliximab Biosimilar

On the 21st of April, the FDA approved another infliximab biosimilar, called Renflexis (Infliximab-abda) following on the biologics license application of the South Korean manufacturer Samsung Bioepis Co. LTD.  In early developmental trials this agent was also called SB2.

This will be the fifth biosimilar to be FDA approved and the fourth TNF inhibitor.  In 2016, the FDA approved biosimilar versions of etanercept (Erelzi), adalimumab (Amjevita) and infliximab (Infectra or infliximab-dyyb).   This will be the second version of infliximab to hit the market and under the new naming system will have the generic name infliximab-abda.

Renflexis will carry the same indications of the originator (Remicade) including active, moderate-severe, rheumatoid arthritis, ankylosing spondylitis, adult and pediatric Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.

The drug is approved with the same dosing, boxed warnings (serious infections, TB, lymphoma, hepatosplenic T cell lymphoma) and warnings currently found with Remicade and Inflectra. Thus before starting Renflexis, patient must be screened for tuberculosis.

The company had filed for the U.S. FDA approval in March last year. Submitted supplemental data in December 2016 and was granted licensing privileges on 4/21/17. 

The drug is currently approved and in use in Korea under the brand name of Renflexis. It also approved throughout Europe, Norway, Iceland and Australia since 2016, where it is called Flixabi. 

Renflexis will be marketed and distributed in the United States by Merck & Co Inc.

Remicade accounted for about 9.7 percent of Johnson & Johnson's total revenues for fiscal 2016, and biosimilar competition is expected to reduce U.S. sales.

The package insert for Renflexis can be found here.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

CALM Study: Tight Control with Anti-TNF Wins in Crohn's Disease

Not unlike rheumatoid arthritis and other inflammatory disorders, therapeutic efficacy in Crohn's disease (CD) is often assessed clinically. There is growing use and interest in biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein. But Lancet has now reported a clinical trial has shown that a tight control strategy can yield better responses to TNF inhibitors when compared to usual care. 

Amgen-Abbvie Settle Humira Biosimilar Patent Dispute

Amgen's biosimilar version of adalimumab (Humira) was FDA-approved in September 2016 and given the trade name Amjevita (generic: adalimumab-atto). This new TNF inhibitor biosimilar has not yet been to market because of legal wranglings over patent issues by Abbvie's Humira.

Another Adalimumab Biosimilar Approved

On Friday August 25th, the FDA approved another adalimumab biosimilar: Cyltezo (generic name: adalimumab-adbm).

Adalimumab Biosimilars Adding Up

Reuters reports that yet another adalimumab biosimilar has been approved by European Union regulators.

The new drug is named Imraldi, and is manufactured by Samsung Bioepis, a company who has several biosimilars approved or in development for worldwide use.

It's Rheumatoid Arthritis, not the TNF inhibitor, that Drives Lymphoma Risk

Evidence from multiple studies suggests there is an increased risk of lymphoma in rheumatoid arthritis (RA) that is believed to be linked to the cumulative activity of the disease.